The Phase 1b trial was a randomized, double-blind, placebo-controlled, 4-week crossover study involving 43 patients. The study cohort consisted of 23 patients with chronic osteoarthritic pain (COAP) and 20 patients with chronic low back pain (CLBP). PIPE-791 was administered as a once-daily 10mg oral dose. The trial met its primary safety and tolerability objectives, with no serious adverse events reported. Patients treated with PIPE-791 showed numerical improvements in pain intensity scores (PI-NRS) compared to placebo, particularly in the COAP subgroup.